Hard to imagine a generic pharma co like MYX doing 400 million revenue
and not delivering 30% NPAT
which is more like a norm rather than an exception.
That will come to 100-120 million NPAT and eps of 1-1.5 dollars and stock price 20-40 range.
What is wrong and where in MYX.
There is no rocket science here.
Even if MYX downsize to 200 million revenue wisely and delivers 20-30 % NPAT
it is wiser as stock can hit new all time highs rather than rotting here.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.03 |
Change
-0.170(3.27%) |
Mkt cap ! $408.6M | |||
| Open | High | Low | Value | Volume |
| $5.20 | $5.21 | $5.03 | $2.804M | 555.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14654 | $5.03 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.14 | 3111 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |